Across TCGA cell cohorts, SPRY4 mutation is significantly associated with the drug of many other genes, with 3 significant associations in total. BLOOD_Leukemia shows the largest number of these associations.

The most reproducible SPRY4-associated genes across cancer lineages are Pevonedistat, OSU-03012, and Uprosertib. Each is linked with SPRY4 in more than 1 cancer types. Because this analysis shows association rather than direction, both SPRY4-to-partner and partner-to-SPRY4 results are reported.

Each partner links to its own Q-omics profile.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (SPRY4→partner) and Y-score (partner→SPRY4) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	Pevonedistat →	-0.424	-3.000	.014	.028	3	1
BLOOD_Leukemia	OSU-03012 →	+0.407	+3.082	<.001	.012	1	1
BLOOD_Leukemia	Uprosertib →	+0.519	+2.853	.013	.026	1	1

Each partner links to its Q-omics profile. Showing the 3 strongest of 3 associations by consensus.

Exploration

SPRY4 survival (RNA) · tumor vs normal (RNA) · all SPRY4 data types